Reimagine Cancer Detection, Diagnosis & Patient Management through Harnessing the Potential of Liquid Biopsies

In the past year, the detection and characterization of fluid-based biomarkers in oncology witnessed an unprecedented level of progress, investment and industry partnership announcements. However, as the liquid assay landscape matures and the level of sensitivity and selectivity achieved by assays creates excitement for precision drug development, there remains a number of unique hurdles to translate rapid technical advancements towards the development of more effective and accessible precision oncology treatments.

That’s why the 6th Liquid Biopsy for Precision Oncology Summit took place digitally in February, providing you with a valuable industry touchpoint to network, collaborate and learn directly from your peers at an exciting time for precision medicine.

As industry’s most comprehensive liquid biopsy meeting, uniting 600 key decision makers including Pfizer, AstraZeneca, Mirati Therapeutics, Kura Oncology, GSK, BloodPAC, International Society of Liquid Biopsy, Guardant Health, Natera and many more to address the key scientific, technical, regulatory, commercial and testing access challenges associated with progressing precision oncology pipelines harnessing liquid biopsy technology.

Exploring how a breadth of methods including ddPCR, single-cell genotypic & phenotypic analysis, in addition to pan-cancer, comprehensive NGS & tumor-informed assays are enabling detection screening, earlier diagnosis, resistance and recurrence monitoring – in turn facilitating quicker and more informed treatment decision-making in precision drug development.

Attendees joined to witness first-hand the clinical utility of ctDNA, cfDNA, miRNA & CTC analysis in the precision oncology pipelines of 30+ scientific & commercial biopharma academic experts successfully advancing immunotherapy and targeted candidates toward patients.

A prime opportunity to meet diverse stakeholders and discover the most cutting-edge scientific data to strengthen your pipeline and capitalize on the vast amount of progress the field is witnessing.

A crucial annual date on the precision oncology’s industry calendar – It’s not to be missed!

Andrew Allen

President, Chief Executive Officer & Co-Founder

Gritstone bio

Benoit Destenaves

Executive Director, Head of Biomarkers & Companion Diagnostics

H3 Biomedicine

Dana Connors

Scientific Program Manager, Cancer Research Partnerships

Foundation for the National Institutes of Health

David Gandara

Professor, Director, Thoracic Oncology Program; Chief Medical Officer

UC Davis Comprehensive Cancer Center; International Society for Liquid Biopsy

Fernando Cruz-Guilloty

Scientific Director, Oncology Diagnostics


Harris S. Soifer

Executive Director, Clinical Biomarkers & Companion Diagnostics

Kura Oncology

Jean-Francois Martini

Senior Director, Translational Oncology Lead, Global Product Development


Jonathan Beer

Global Precision Medicine Strategic Intelligence Lead


Julie Ramage

Director of Precision Medicine Quality Initiatives & Partnerhips


Kelly Shanahan


Living with Metastatic Breast Cancer

Kenna Anderes

Vice President Translational Medicine & Companion Diagnostics

Mirati Therapeutics

Klaus Pantel

Chairman, Institute Director

University Medical Center Hamburg-Eppendorf

Koustubh Ranade

Head of Translational Medicine


Lauren Leiman

Executive Director


Marjorie Petty

Senior Director, Operations & Medical Development

Spectrum Pharmaceuticals

Minetta Liu

Research Chair, Department of Oncology; Consultant, Department of Laboratory Medicine and Pathology

Mayo Clinic

Partha Das

Medical Director, CDx & Biomarker Strategy


Pashtoon Kasi

Director Colon Cancer Research; Precision Medicine Director for Liquid Biopsy Research

Weill Cornell Medicine; Englander Institute of Precision Medicine

Qu Zhang

Director, Clinical Biomarkers, ImmunoOncology


Steven Piccoli

Head of Clinical Biomarkers


Don’t take our word for it! Here’s what past attendees had to say at last year’s digital meeting!

“I learned the latest progress in use of liquid biopsy in both the research and clinical setting. Wouldn't miss this meeting” – Genentech


““Extremely informative sessions which provide insight into both the clinical and commercial potential of liquid biopsy” – Myriad Genetics


“Liquid Biopsy has finally come of age as evident by the speakers and presentations given at the Liquid Biopsy Summit” – Regeneron

Lead Partner


Expertise Partners

tempus-logo-vector (002)

Program Partners

Burning Rock cropped (002)
epic sciences logo
Inivata logo
angle-logo-2x (002)
Personalis (002)
Biodesix (002)

Spotlight Partner

PGDx logo (002)

Panel Partners

agilent (002)
1200px-Qiagen_Logo.svg (002)

Other Events in the Series